Citation data

OpenAlex

Works that cite this article, indexed by OpenAlex.

11 resultsUpdated October 23, 2026
1

Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals

Hepatitis Monthly 16(4) (2016)

Khashayar Hesamizadeh; Heidar Sharafi; Mohammad Saeid Rezaee Zavareh; Bita Behnava; Seyed Moayed Alavian

2

New use of an old drug: chloroquine reduces viral and ALT levels in HCV non-responders (a randomized, triple-blind, placebo-controlled pilot trial)

Canadian Journal of Physiology and Pharmacology 94(6) (2016)

Payam Peymani; Behzad Yeganeh; Siamak Sabour; Bita Geramizadeh; Mohammad Reza Fattahi; Hossein Keyvani; Negar Azarpira; Kevin M. Coombs; Saeid Ghavami; Kamran Bagheri Lankarani

3

Occult HCV Infection: The Current State of Knowledge

Iranian Red Crescent Medical Journal 17(11) (2015)

Mohammad Saeid Rezaee Zavareh; Reza Hadi; Hamidreza Karimi‐Sari; Mohammad Hossein Khosravi; Reza Ajudani; Fardin Dolatimehr; Mahdi Ramezani‐Binabaj; Seyyed Mohammad Miri; Seyed Moayed Alavian

4

A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection

Iranian Red Crescent Medical Journal 18(11) (2016)

Seyed Moayed Alavian; Shekoufeh Nikfar; Abbas Kebriaeezadeh; Farhad Hosseinzadeh Lotfı; Ehsan Sanati; Mohsen Rezaei Hemami‬; Khosro Keshavarz

5

Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C

Hepatitis Monthly 21(8) (2021)

Zahra Goudarzi; Abdollah Poursamad; Iman Karimzadeh; Nahid Jallaly; Khosro Keshavarz; Seyed Moayed Alavian

6

Evaluation of Direct-acting Antiviral Drugs for Hepatitis C patients below 30 years age in Sialkot, Pakistan

Pakistan Journal of Medical and Health Sciences 16(9) (2022)

Kashif Waqas; Bushra Noreen; Zoya Muzaffar; Furqan Sabir; Syed Zeeshan Haider Naqvi; Javed Anver Qureshi; Faheem Hadi; M. Khawar Abbas

7

Evaluation of Direct-acting Antiviral Drugs for Hepatitis C patients below 30 years age in Sialkot, Pakistan

Pakistan Journal of Medical and Health Sciences 16(11) (2022)

Kashif Waqas; Bushra Noreen; Zoya Muzaffar; Furqan Sabir; Syed Zeeshan Haider Naqvi; Javed Anver Qureshi; Faheem Hadi; M. Khawar Abbas

8

Budget impact analysis of glecaprevir/pibrentasvir treatment for hepatitis C in Iran: a modelling study

BMJ Open 15(9) (2025)

Mojtaba Jafari; Parisa Mehdizadeh; Khosro Keshavarz; Ehsan Teymourzadeh; Mohammad Ali Abyazi; Parsa Gholamreza Shirazi

9

The Quest for Optimal Therapy: Sofosbuvir and Ribavirin in Chronic Hepatitis C - A Systematic Review

Journal For International Medical Graduates 2(2) (2023)

Monica D Yerramsetti; Olawale O Olanisa; Payal Jain; Qasim S Khan; Abhijith C Vemulapalli; Abanob A Elias; Samia Rauf Butt

10

A cost-utility analysis of Glecaprevir/Pibrentasvir versus Sofosbuvir/Daclatasvir and Sofosbuvir/Velpatasvir for treatment of hepatitis C in Iran

Cost Effectiveness and Resource Allocation 23(1) (2025)

Mojtaba Jafari; Parisa Mehdizadeh; Khosro Keshavarz; Ehsan Teymourzadeh; Mohammad Ali Abyazi; Seyed Moayed Alavian; Pouria Alijanpour

11

Economic evaluations of Glecaprevir/Pibrentasvir and Grazoprevir/Elbasvir for the treatment of hepatitis C: a systematic review

Cost Effectiveness and Resource Allocation 24(1) (2025)

Mojtaba Jafari; Parisa Mehdizadeh; Ehsan Teymourzadeh; Mahmood Salesi; Khosro Keshavarz; Mohammad Ali Abyazi; Mohammad Heiat; Seyed Moayed Alavian